Among the 51 patients who developed HCC, 26 (51%) were male with a median of age 60 (IQR 54–66) years and had serum AFP level of 12.2 (IQR 6.1–18.8) ng/mL at the start of DAA treatment. This evidence concerns the gene AFP and hepatocellular carcinoma.